Imatinib Basics

Imatinib, the active ingredient in Imatinib Basics, is a tyrosine kinase inhibitor presented as a tablet for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumors in adult patients.

GNH USA supplies Imatinib Basics as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Imatinib targets specific tyrosine kinases involved in malignant cell growth, making it useful for several hematologic and solid‑tumor indications. - Chronic Myeloid Leukemia (CML): reduces abnormal white‑blood‑cell proliferation and improves long‑term survival. - Gastrointestinal Stromal Tumor (GIST): inhibits tumor growth and delays disease progression. - Philadelphia chromosome‑positive Acute Lymphoblastic Leukemia (Ph+ ALL): provides targeted therapy for this specific leukemia subtype.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea: mild to moderate upset stomach. - Edema: swelling of the hands, feet, or face. - Muscle cramps: painful tightening of skeletal muscles. - Fatigue: persistent tiredness. - Diarrhea: loose stools. - Rash: skin irritation or redness.

Serious or Rare Side Effects: - Severe neutropenia: dangerously low white‑blood‑cell count. - Hepatotoxicity: liver enzyme elevations or liver injury. - Cardiac failure: reduced heart pumping ability. - Pulmonary hypertension: high blood pressure in lung arteries. - Stevens‑Johnson syndrome: severe skin reaction. - Hemorrhage: abnormal bleeding events.

Patients should be monitored closely for safety concerns before and during therapy. - Blood count monitoring: perform regular CBC to detect cytopenias. - Liver function assessment: check ALT/AST levels periodically. - Cardiac evaluation: assess for signs of heart failure or hypertension. - Pregnancy avoidance: drug is contraindicated in pregnancy due to unknown risks. - Drug interaction review: evaluate concomitant medications for CYP3A4 effects. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Imatinib may interact with several medicines that affect its metabolism or increase toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may raise imatinib levels. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy. - Antacids containing aluminum or magnesium: can lower absorption. - QT‑prolonging agents (e.g., sotalol, quinidine): increase risk of cardiac arrhythmias. - Warfarin: may enhance anticoagulant effect.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., fluconazole): may modestly increase exposure. - CYP3A4 substrates (e.g., statins): monitor for altered lipid‑lowering effect. - Diuretics (e.g., furosemide): watch for electrolyte disturbances. - NSAIDs: increased risk of gastrointestinal bleeding. - Vaccines (live attenuated): potential reduced efficacy.